NEW YORK and CAESAREA, Israel, Aug.
6, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq:
DRIO) ("DarioHealth" or "Dario"), a leading global, digital
therapeutics company and member of the Digital Therapeutics
Alliance (DTx), today announced its plan to present the results of
a new Dario app user study at the upcoming annual conference of the
American Association of Diabetes Educators (AADE) in Houston, Texas on August 9-12, 2019.
The study, which began in October
2018 and continued until April
2019, included 162 Dario app users who participated in the
Dario Coaching Program that the company offers through its digital
MyDario™ app. The digital blood-glucose and blood-pressure
monitoring app is available on iPhone or Android phones.
The results of the study demonstrate that DarioHealth's digital
therapeutic solution achieves clinically proven results and helps
improve the blood-glucose levels and overall health of users
managing Type 2 Diabetes. The results of the study also emphasize
the importance of personalized coaching interventions in helping
users achieve in-range glucose levels. Achieving and maintaining
In-range glucose levels is, not only a key indicator of the
efficacy of the MyDario™ app, but also an effective tool for a
user to measure how his or her body reacts to various foods,
exercise and other stimuli.
"We are excited to present our new study at the AADE conference
because the results show that well-designed digital therapies can
have a meaningful and substantial positive impact on the health of
digital app users, which is a central goal of ours," said
Olivier Jarry, DarioHealth President
and Chief Operating Officer. "Our clinical results show how digital
therapeutic interventions can be an indispensable tool for
individual users, employers, healthcare providers, insurance
companies and clinics to create user engagement and improve the
health outcomes of individuals with chronic illness."
To learn more about our study results and DarioHealth's digital
therapeutic solutions, please visit us at the AADE conference Booth
#1236. The final results of the study will also be published via
press release in conjunction with the event.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global Digital
Therapeutics (DTx) company revolutionizing the way people manage
their health across the chronic condition spectrum. By delivering
evidence-based interventions that are driven by data, high-quality
software and coaching, we developed a novel approach that empowers
individuals to adjust their lifestyle in a personalized way. Our
cross-functional team operates at the intersection of life
sciences, behavioral science and software technology to deliver
highly engaging therapeutic interventions. Dario is one of the
highest-rated diabetes solutions and its user-centric digital app
is loved by tens of thousands of consumers around the globe.
DarioHealth is rapidly moving into new chronic conditions and
geographic markets, using a performance-based approach to improve
the health of users managing chronic disease. To learn more about
DarioHealth and its digital health solutions via the Dario mobile
app, please go to: http://mydario.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company discusses
the timing of the release of the study data and that such data
underscores clinical evidence of improvements in chronic
conditions, such as diabetes, through the use of the Dario app,
that the data emphasizes the importance of personalized coaching
interventions in helping users achieve in-range glucose levels,
that the data shows that well-designed digital therapies such as
the Dario app can have a meaningful and positive impact on the
health of users and that the clinical results show how digital
therapeutic interventions can be an indispensable tool for
individual users, employers, healthcare providers, insurance
companies and clinics to create user engagement and improve the
health outcomes of individuals with chronic illness, it is using
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1-347-767-4220
Media Inquiries:
Catherine
Polisi Jones
Polisi Jones Communications
cjones@polisijones.com
+1-917-330-8934
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-to-present-new-data-at-aade-conference-that-shows-improvement-of-type-2-diabetes-blood-glucose-levels-using-mydario-app-300897092.html
SOURCE DarioHealth Corp.